← Back to Screener
Fortrea Holdings Inc. Common Stock (FTRE)
Price$10.09
Favorite Metrics
Price vs S&P 500 (26W)-4.78%
Price vs S&P 500 (4W)-4.72%
Market Capitalization$939.67M
All Metrics
P/CF (Annual)8.28x
Book Value / Share (Quarterly)$6.05
P/TBV (Annual)2.37x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-4.19%
Cash Flow / Share (Quarterly)$0.95
Price vs S&P 500 (YTD)-44.38%
Gross Margin (TTM)18.50%
Net Profit Margin (TTM)-36.21%
EPS (TTM)$-10.90
10-Day Avg Trading Volume0.90M
EPS Excl Extra (TTM)$-10.90
Revenue Growth (5Y)1.09%
EPS (Annual)$-10.81
ROI (Annual)-61.02%
Gross Margin (Annual)18.50%
Net Profit Margin (5Y Avg)-7.95%
Cash / Share (Quarterly)$1.88
Revenue Growth QoQ (YoY)-5.24%
ROA (Last FY)-36.31%
Revenue Growth TTM (YoY)1.00%
EBITD / Share (TTM)$-8.57
ROE (5Y Avg)-38.36%
Operating Margin (TTM)-32.04%
Cash Flow / Share (Annual)$0.95
P/B Ratio1.67x
P/B Ratio (Quarterly)2.83x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)0.67x
Net Interest Coverage (TTM)-7.31x
ROA (TTM)-34.56%
EV / EBITDA (TTM)79.04x
EPS Incl Extra (Annual)$-10.81
Current Ratio (Annual)0.98x
Quick Ratio (Quarterly)0.84x
3-Month Avg Trading Volume1.52M
52-Week Price Return87.50%
EV / Free Cash Flow (Annual)20.59x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.29
P/S Ratio (Annual)0.34x
Asset Turnover (Annual)1.00x
52-Week High$18.67
Operating Margin (5Y Avg)-5.13%
EPS Excl Extra (Annual)$-10.81
CapEx CAGR (5Y)0.98%
26-Week Price Return-0.79%
Quick Ratio (Annual)0.91x
13-Week Price Return-45.38%
Total Debt / Equity (Annual)1.87x
Current Ratio (Quarterly)0.98x
Enterprise Value$1,817.875
Revenue / Share Growth (5Y)0.50%
Asset Turnover (TTM)0.95x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-36.09%
Cash / Share (Annual)$1.88
3-Month Return Std Dev74.47%
Gross Margin (5Y Avg)19.61%
Net Income / Employee (TTM)$-0
ROE (Last FY)-175.01%
Net Interest Coverage (Annual)-7.31x
EPS Basic Excl Extra (Annual)$-10.81
P/FCF (TTM)4.36x
Receivables Turnover (TTM)4.36x
EV / Free Cash Flow (TTM)20.59x
Total Debt / Equity (Quarterly)1.87x
EPS Incl Extra (TTM)$-10.90
Receivables Turnover (Annual)4.36x
ROI (TTM)-55.09%
P/S Ratio (TTM)0.34x
Pretax Margin (5Y Avg)-7.03%
Revenue / Share (Annual)$29.86
Tangible BV / Share (Annual)$7.88
Forward P/E14.90x
Free OCF CAGR (5Y)-12.97%
Price vs S&P 500 (52W)57.67%
Year-to-Date Return-41.74%
5-Day Price Return7.14%
EPS Normalized (Annual)$-10.81
ROA (5Y Avg)-7.87%
Net Profit Margin (Annual)-36.21%
Month-to-Date Return6.69%
EBITD / Share (Annual)$-8.63
Operating Margin (Annual)-32.04%
LT Debt / Equity (Annual)1.86x
P/CF (TTM)8.28x
ROI (5Y Avg)-13.24%
LT Debt / Equity (Quarterly)1.86x
EPS Basic Excl Extra (TTM)$-10.90
P/TBV (Quarterly)3.29x
P/B Ratio (Annual)2.83x
Pretax Margin (TTM)-36.09%
Book Value / Share (Annual)$6.05
Price vs S&P 500 (13W)-46.07%
Beta1.76x
P/FCF (Annual)10.64x
Revenue / Share (TTM)$29.26
ROE (TTM)-152.17%
52-Week Low$3.97
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
2.81
3.65
3.71
3.76
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.09 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $196.11 |
LHLabcorp Holdings Inc. | 25.08x | 7.25% | 9.92% | 10.28% | $266.36 |
DGXQuest Diagnostics Inc. | 21.24x | 11.78% | 14.10% | 13.88% | $191.46 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $85.70 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $60.09 |
VCYTVeracyte, Inc. | 40.04x | 16.01% | 11.17% | 5.33% | $33.03 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $49.47 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $22.42 |
CSTLCastle Biosciences, Inc. Common Stock | 47.31x | 3.66% | -12.44% | -5.27% | $24.56 |
About
Fortrea is a global contract research organization providing comprehensive clinical trial management, pharmacology, and patient access solutions for biopharma, medical device, and diagnostic companies. The company offers flexible engagement models ranging from functional services to full-service trial management. Spun off from Labcorp in 2023, Fortrea operates as an independent public company with approximately 19,000 employees across 90 countries.